SiSaf’s Bio-Courier Technology Enables Clinical Trial Success for Topical Treatment of Mild to Moderate Alopecia Areata
10. Juni 2024 04:00 ET
|
SiSaf Ltd
Positive topline results in a Phase II clinical trial of a licensee’s alopecia treatment using the ProSilic® variant of SiSaf’s Bio-Courier® delivery technology Formulation of the small molecule drug...
Peer-Reviewed Publication of Positive Preclinical Data of SiSaf’s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis
18. September 2023 04:00 ET
|
SiSaf Ltd
GUILDFORD, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA therapeutics company, is pleased to announce the publication in the peer-reviewed journal Molecular Therapy Nucleic...
SiSaf Appoints Nikos Tzagkarakis in the New Role of Chief A.I. Officer
13. Juli 2023 04:00 ET
|
SiSaf Ltd
GUILDFORD, England, July 13, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I....
FDA Grants SiSaf’s Innovative siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation for the Treatment of Autosomal Dominant Osteopetrosis
15. Mai 2023 03:00 ET
|
SiSaf Ltd
GUILDFORD, England, May 15, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA delivery and therapeutics company, announces that SIS-101-ADO, its siRNA therapeutic for patients with Autosomal Dominant...
SiSaf Appoints Dr. Richard Goodfellow to Board of Directors
05. April 2023 03:00 ET
|
SiSaf Ltd
GUILDFORD, England, April 05, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announced that it has appointed Dr. Richard Goodfellow to its Board of Directors. ...
SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer
02. März 2023 04:00 ET
|
SiSaf Ltd
GUILDFORD, United Kingdom, March 02, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announces its collaboration with the University of Leipzig, Germany, to develop...
SiSaf Establishes Strategic Partnership with Avellino Labs USA to Co-Develop Non-Viral, Topical Gene Therapies for Corneal Dystrophy
18. Dezember 2019 09:21 ET
|
SiSaf Ltd
LONDON, Dec. 18, 2019 (GLOBE NEWSWIRE) -- SiSaf Ltd, pioneers of Bio-Courier® technology, today announced it has entered into a strategic collaboration with Avellino Labs USA, Inc., a leader in...